D Friedman, JS Parker, JA Kimble, FÇC Delori… - RETINA, 2011 - journals.lww.com Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. ... Skip Navigation Links Home > ...
SM Risard, DJ Pieramici, MD Rabena, JC Basefsky… - Retina, 2011 - journals.lww.com Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. ... Skip Navigation Links Home > Current ... Cited by 1 - Related articles - All 4 versions
JI Lim, AE Fung, M Wieland, D Hung… - Ophthalmology, 2011 - Elsevier Patients received a single intravitreal injection of IBI-20089 using a sequential dose escalation schedule. Each cohort consisted of 5 patients who received the intravitreal injection of the sustained liquid drug delivery system containing either 6.9 mg (25 μl) triamcinolone acetonide (TA; ... Related articles - All 3 versions
[PDF] from blind.isK Zhang, JJ Hopkins, JS Heier… - Proceedings of the …, 2011 - National Acad Sciences There is no treatment available for vision loss associated with advanced dry age-related macular degeneration (AMD) or geographic atrophy (GA). In a pilot, proof of concept phase 2 study, we evaluated ciliary neurotrophic factor (CNTF) delivered via an intraocular encapsulated ... Cited by 3 - Related articles - All 4 versions
J Ambati - Investigative Ophthalmology & Visual Science, 2011 - ARVO It is notable that the first human trials of siRNAs were conducted in the eye. siRNAs targeting VEGF-A (bevasiranib) or one of its receptors VEGFR-1 (siRNA-027/AGN 211745) were tested as intravitreously administered drug candidates in clinical trials in patients with CNV due ... Related articles - All 2 versions